SCHEMBL4401320

SCHEMBL4401320

NC(=O)CS(=O)(=O)Nc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
HPGD P15428 3/20 0.49
LMNA P02545 1/20 0.49
KEAP1 Q14145 2/20 0.45
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44
IL1RN P18510 1/20 0.44
ERAP1 Q9NZ08 1/20 0.44
TMPRSS6 Q8IU80 2/20 0.44
KMT2A Q03164 4/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41
NR3C2 P08235 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM1A O60341 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831034 0.84 HPGD (0.51) CA1CA2HPGDLMNAKEAP1
SCHEMBL10772858 0.81 HPGD (0.53) CA1CA2HPGDLMNAKEAP1
SCHEMBL6202161 0.79 HPGD (0.56) CA1CA2HPGDLMNAKEAP1
SCHEMBL832208 0.78 HPGD (0.50) CA1CA2HPGDLMNAKEAP1
SCHEMBL3923476 0.75 CA1 (0.58) CA1CA2HPGDLMNAKEAP1
SCHEMBL15672897 0.74 CA2 (0.56) CA1CA2HPGDLMNAKEAP1
SCHEMBL6533144 0.74 CA1 (0.56) CA1CA2HPGDLMNAKEAP1
Acetic Acid SCHEMBL27557152 0.74 HPGD (0.69) CA1CA2HPGDLMNAKEAP1
SCHEMBL1020182 0.74 CA1 (0.56) CA1CA2KEAP1CA12CA9
SCHEMBL4557719 0.73 CYP2C19 (0.43) CA1CA2LMNACA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 CA1 4150/4885CA2 3039/4885HPGD 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.